Three different prognostic subgroups have been described depending on tumor localization and type of fusion gene, with (i) the best median OS in patients with non-thoracic non-BRD4:NUTM1 fusion carcinoma (36.5 months from initial cancer diagnosis), (ii) a median prognosis for non-thoracic disease with BRD4::NUTM1 fusion (10 months) and (iii) the worst prognosis (4.4 months) in patients with thoracic disease onset, independent of the fusion gene partner (2). This evidence concerns the gene NUTM1 and cancer.